MedTrace Logo

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

NCT00187005 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2011-03-30

No results posted yet for this study

Summary

The main purpose of this study is to find out if radiation to the central nervous system (CNS) can be safely omitted with early intensification of chemotherapy and chemotherapy given directly to the CNS. Another purpose is to find out if survival of children with ALL can be improved with risk-directed therapy given on this protocol.

Conditions

Interventions

DRUG

Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase

See Detailed Description section for details of treatment interventions.

DRUG

L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine

See Detailed Description section for details of treatment interventions.

Sponsors & Collaborators

Principal Investigators

  • Ching-Hon Pui, MD · St. Jude Children's Research Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-07-31
Primary Completion
2002-07-31
Completion
2002-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187005 on ClinicalTrials.gov